Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06602193
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-16
Brief Title:
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinsons Disease LRRK2-PD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinsons Disease LRRK2-PD
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 2a multicenter randomized 12-week double-blind placebo-controlled parallel-group study followed by an OLE is designed to evaluate the safety tolerability and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD LRRK2-PD is defined as Parkinsons Disease PD in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None